Important Information for Investors: Upcoming Deadline to File a Lead Plaintiff Motion in the Zynex, Inc. Securities Class Action
BENSALEM, Pa. – The Law Offices of Howard G. Smith announces that a deadline is approaching for investors who purchased Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023, and March 11, 2025, inclusive (the “Class Period”), to file a lead plaintiff motion in the securities class action filed on behalf of these investors. If you are an investor who suffered a loss in Zynex during the Class Period, you may contact the Law Offices of Howard G. Smith to learn more about your rights and potential remedies.
Background
Zynex is a medical device and technology company that designs, manufactures, and markets non-invasive medical devices and therapeutic devices for medical, surgical, orthopedic, and rehabilitation applications. The Company’s products include transcutaneous electrical nerve stimulation (“TENS”) devices, functional electrical stimulation (“FES”) devices, and other medical devices.
Allegations
The securities class action alleges that Zynex and certain of its executives made false and misleading statements and failed to disclose material information during the Class Period. Specifically, the complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that:
- Zynex was experiencing declining sales and revenue due to increased competition and decreased demand for its products;
- The Company’s financial statements for the fiscal years ended December 31, 2022, and 2023 contained material misstatements and omissions;
- Zynex was experiencing operational challenges, including difficulties in managing its supply chain and production processes;
- The Company was experiencing increased regulatory scrutiny and faced potential regulatory action.
Impact on Individual Investors
The securities class action against Zynex may have significant consequences for individual investors who purchased the Company’s securities during the Class Period. If the allegations in the complaint are proven, these investors may be entitled to recover their losses through the securities class action. The Law Offices of Howard G. Smith encourages investors with substantial losses to contact the firm to discuss their options for pursuing a recovery.
Impact on the World
The securities class action against Zynex also has potential implications beyond the individual investors who purchased the Company’s securities during the Class Period. The allegations in the complaint, if proven, could undermine confidence in the accuracy and reliability of Zynex’s financial reporting and governance. Moreover, the regulatory scrutiny and potential regulatory action facing the Company could result in increased oversight and regulation of the medical device industry more broadly. As such, the outcome of the securities class action could have significant ripple effects throughout the industry and the broader financial markets.
Conclusion
The Law Offices of Howard G. Smith reminds investors of the upcoming May 19, 2025, deadline to file a lead plaintiff motion in the securities class action against Zynex, Inc. If you purchased Zynex securities during the Class Period and suffered a loss, you may be entitled to recover your losses through the securities class action. The Law Offices of Howard G. Smith encourages you to contact the firm to discuss your options for pursuing a recovery. The outcome of the securities class action could have significant implications for individual investors and the broader financial markets.
Additionally, the allegations in the complaint, if proven, could have far-reaching consequences for the medical device industry and regulatory oversight more broadly. As such, it is important for investors to stay informed about the developments in this case and the broader industry trends.
For more information about the securities class action against Zynex, or to discuss your legal options, please contact the Law Offices of Howard G. Smith at 888-637-5520 or by email to [[email protected]](mailto:[email protected]).
